Experimental obesity mimics infectious surgery

The drug depends on the research conducted at the Massachusetts Institute of Technology by Giovanni Travers

Discover the two mechanism when working on a way to develop liquid medicine formulas that can be granted to children. Soon they realized that they could make this temporary industrial paint more or less permeable, either to enhance or slow down absorption. That last ability was attractive as a treatment for obesity.

“This substance is something that you will take as a capsule or liquid, but the next day it went because of its natural rotation of our mucous surface in the digestive system,” says Traverso. He and Lenger postponed Syntis with Dhanda in 2022. This paint is similar to what the mussels and other shells are used to stick to rocks or ocean bottom.

In the results announced by Syntis, the drug was delivered in the form of a liquid through a tube directly to the small intestine so that researchers can check that polymers form as expected. The shape of a tablet is already tested in pigs and dogs, and this is what Syntis plans to test in future human studies.

In mice, the drug produced a 1 % weekly weight weight loss for six weeks while maintaining 100 percent of meager muscle mass.

In a experimental study in the first nine participants, the drug was safe without any harmful effects. The tissue samples taken from the intestine were used to confirm that the paint was formed and was also wiped from the body within 24 hours. The study was not designed to evaluate weight loss, but the blood test showed that after giving the medicine, the levels of glucose and hormone “hunger” were less while the levels of leptin, which is an appetite regulation hormone, was higher.

“When the nutrients are later redirected in the intestine, you stimulate the paths that lead to satiety, energy expenses, weight loss in general and sustainable,” says Danda.

The results of Syntis Bio in animals also alludes to the drug’s potential for weight loss without compromising the muscle block, one of the concerns related to the current GLP-1 drugs. While weight loss in general is related to many health benefits, there Growth certificate This type of sharp weight loss by GLP-1 can also lead to meager muscle loss.

Louis Aaron, obese medicine and professor of metabolic research at Will Cornell Medical College, says, although the GLP-1 is very common, it may not be suitable for everyone. It is expected that in the non -distant future, there will be many drugs for obesity and treatment that will be more customized. “I think the syntis compound fits just as a treatment that can be used early. It is a kind of thing that you can use as a medicine in the first line,” he says. Marrone works as a clinical consultant for the company.

Vladimir Kushner, professor of medicine and coastal theorizing director at Washington University in Saint -Louis, who is not involved in Syntis, says early experimental data is encouraging, but it is difficult to extract any conclusions from this small study. It expects the medicine to make people feel a hook, but they can also have some side effects such as deduction surgery in the stomach. He says: “My expectation is that this will have some side effects of the digestive system, such as bloating and spasm in the abdomen, as well as some diarrhea and nausea once it reaches a greater study.”

It is the first days of this new technique, but if it is proven effective, it may one day be an alternative or additional medicine for the GLP-1 drugs.